A Phase 3 interventional study of Rivaroxaban 10 MG in Venous Thromboembolism and Cancer, sponsored by Ottawa Hospital Research Institute. Recruiting at 11 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-09.
Sponsored by Ottawa Hospital Research Institute · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.
Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 11th largest by planned enrollment, is one of 2 that started in 2022, is one of 26 in phase 3, reaches primary completion later than 7 of the 17 other live ones, and was the 42nd registered.
714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:
Military Hospital of Tunis · Sites in Tunisia
Ages 18–80
Wolfson Medical Center · Sites in Israel
Ages 18–50 · Women only
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Thomas Jefferson University · Sites in United States
Ages 18+ · Women only
Medical University of Gdansk · Sites in Poland
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 29 · Phase 4 12
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,828 is above the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 272 across the 61 interventional studies. Of the 40 that completed or were terminated, 14 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 61 have an industry lead sponsor. The 10 most frequent:
Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.
21 studies in Venous Thromboembolism by Ottawa Hospital Research Institute: 6 open now, 6 under way, 5 of them phase 3. Of 12 finished, 4 (33%) have results posted.
Among the 21 studies in Venous Thromboembolism by Ottawa Hospital Research Institute, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is one of 5 in phase 3, and was the 17th registered.
Ottawa Hospital Research Institute’s Venous Thromboembolism studies by the year they started, since 2002.
8 of the studies testing rivaroxaban in Venous Thromboembolism that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05029063Phase 3Ottawa Hospital Research InstitutePrimary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters | 2026-12 |
| NCT07228663Phase 3McMaster UniversityHip Fracture Surgery Arterial and Venous Thrombotic Events Prevention | 2027-07-01 |
| NCT06580223Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | 2027-09-01 |
| NCT04874428Insel Gruppe AG, University Hospital BernDirect Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | 2026-12 |
| NCT07907211Chen LijuanAspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 61 studies testing rivaroxaban in Venous Thromboembolism, from their registry updates:
Among Ottawa Hospital Research Institute’s 21 in Venous Thromboembolism:
This tab as a report to print or save as PDF → With an account.
The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
TRIM-Line is a double blind randomized controlled trial comparing rivaroxaban 10mg po daily vs placebo in patients with active cancer and indwelling CVC. This will involve 9 centers across Canada.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
History of condition at increased bleeding risk including, but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rivaroxaban 10mg OD
Drug: Rivaroxaban 10 MG
Identical Placebo 10mg OD
Drug: Rivaroxaban 10 MG
Identical comparator drug
Also known as: Placebo
Major VTE prevention
Number of Major VTE's in patient population
Time frame: 90 days (± 3 days) of randomization
Episodes of Major Bleeding
Number of participants who had a major bleed
Time frame: 90 days (± 3 days) of randomization
Number of participants with Clinically Relevant Non-Major Bleeding (CRNMB)
As defined by ISTH
Time frame: 90 days (± 3 days) of randomization
Number of patients who had a fatal VTE
Fatal VTE
Time frame: 90 days (± 3 days) of randomization
Number of patients who benefitted from using the experimental intervention
Composite of major VTE and major bleeding
Time frame: 90 days (± 3 days) of randomization
PE
Incidental and Symptomatic
Time frame: 90 days (± 3 days) of randomization
Proximal CVC VTE
Incidental and symptomatic proximal (axillary vein or more proximal) upper extremity CVC-related DVT
Time frame: 90 days (± 3 days) of randomization
Distal CVC VTE
Incidental and symptomatic distal (brachial vein) or proximal (axillary vein or more proximal) upper extremity CVC-related DVT
Time frame: 90 days (± 3 days) of randomization
Proximal Lower extremity DVT
Incidental and symptomatic proximal (popliteal vein or more proximal) lower extremity DVT
Time frame: 90 days (± 3 days) of randomization
Distal Lower extremity DVT
Incidental and symptomatic distal or proximal (popliteal vein or more proximal) lower extremity DVT
Time frame: 90 days (± 3 days) of randomization
Number of participants with Unusual site thrombosis including: splanchnic vein (portal, splenic, superior mesenteric, inferior mesenteric, hepatic) cerebral vein, renal or gonadal vein thromboses
Unusual site thrombosis including: splanchnic vein (portal, splenic, superior mesenteric, inferior mesenteric, hepatic) cerebral vein, renal or gonadal vein thromboses
Time frame: 90 days (± 3 days) of randomization
Number of participants with Superficial upper or lower extremity vein thrombosis
Superficial upper or lower extremity vein thrombosis
Time frame: 90 days (± 3 days) of randomization
Number of participants with an arterial thromboembolic event including: MI, stroke, peripheral arterial disease
Arterial thromboembolic events defined as a diagnostically confirmed final clinical diagnosis of myocardial infarction, stroke or peripheral arterial disease involving the following arterial vascular beds: carotid, upper or lower extremity, gastrointestinal tract, liver, spleen, or kidney
Time frame: 90 days (± 3 days) of randomization
CVC Life-span
Life span of inserted CVC
Time frame: 90 days (± 3 days) of randomization
Number of patients with CVC occlusion occurring after the start of therapy, defined as an obstruction of the CVC lumen that prevents or limits the ability to flush, withdraw blood and/or administer solutions or medications.
CVC occlusion occurring after the start of therapy, defined as an obstruction of the CVC lumen that prevents or limits the ability to flush, withdraw blood and/or administer solutions or medications.
Time frame: 90 days (± 3 days) of randomization
Number of patients with CVC-related blood stream infection defined as the presence of bacteremia originating from the CVC according to the definition from the Centers for Disease Control and Prevention
CVC-related blood stream infection defined as the presence of bacteremia originating from the CVC according to the definition from the Centers for Disease Control and Prevention
Time frame: 90 days (± 3 days) of randomization
Number of participants who passed away during the trial
Overall mortality
Time frame: 90 days (± 3 days) of randomization
EQ-5D-5L Health-related quality of life
Health-related quality of life
Time frame: 90 days (± 3 days) of randomization
ICER
Incremental cost-effectiveness ratio (ICER) at one year
Time frame: 1 Year
Plan to share: No
Started Oct 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.
Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 50 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban
Ottawa Hospital Research Institute →